Definity
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Heart Disease
Conditions
Pulmonary Heart Disease
Trial Timeline
Jul 1, 2009 → Dec 1, 2009
NCT ID
NCT00918866About Definity
Definity is a approved stage product being developed by Lantheus Holdings for Pulmonary Heart Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00918866. Target conditions include Pulmonary Heart Disease.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Heart Disease were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05247541 | Phase 2/3 | Completed |
| NCT03571672 | Phase 3 | Completed |
| NCT03243942 | Phase 2 | Completed |
| NCT01062178 | Phase 2 | Completed |
| NCT00918866 | Approved | Completed |
| NCT01005212 | Pre-clinical | Completed |
Competing Products
20 competing products in Pulmonary Heart Disease